OBJECTIVES To estimate the prevalence and distribution of chronic migraine (CM) in the US population and compare the age- and sex-specific profiles of headache-related disability in persons with CM and episodic migraine. BACKGROUND Global estimates of CM prevalence using various definitions typically range from 1.4% to 2.2%, but the influence of sociodemographic factors has not been completel...

The scale, scope, and significance of humanitarian action have expanded significantly since the late 1980s. This article reflects on two ways in which humanitarianism has been transformed. First, its purpose has been politicized. Whereas once humanitarian actors attempted to insulate themselves from the world of politics, they now work closely with states and attempt to eliminate the root cause...

Migraine headaches are typically episodic in nature and may affect nearly 10% of the population. In addition to treatment, prevention of subsequent episodes or progression to a chronic migraine state is an important therapeutic area. Topiramate is a centrally acting medication approved for both the prevention of seizures and migraine headache. At this time, the exact mechanism of how topiramate...

BACKGROUND Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). METHODS Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinum...

Botulinum toxin A used to treat headache evokes prominent placebo effects and it is likely that these effects are solely responsible for its apparent effectiveness.